| Abstract: |
Objectives: Alkylating agents have activity in well-differentiated pancreatic neuroendocrine tumors (WD panNETs). In glioblastoma multiforme, decreased activity of O6-methylguanine DNA methyltransferase (MGMT) predicts response; in panNETs, MGMT relevance is unknown. Methods: We identified patients withWD panNETs treated with alkylating agents, determined best overall response by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, and performed MGMT activity testing. Results: Fifty-six patients were identified; 26 (46%) of the 56 patients experienced partial response, 24 (43%) of 56 experienced stable disease, and 6 (11%) of 56 experienced progression of disease. O6-methylguanine DNA methyltransferase status was available for 36 tumors. For tumors with partial response, 10 (67%) of 15 were MGMT deficient, and 5 (33%) of 15 were MGMT intact. For tumors with stable disease, 7 (47%) of 15 were MGMT deficient, and 8 (53%) of 15 were MGMT intact. For tumors with progression of disease, 3 (50%) of 6wereMGMT deficient, and 3 (50%) of 6 wereMGMT intact. Conclusions: We observed response and resistance to alkylating agents in MGMT-deficient and MGMT-intact tumors. O6-methylguanine DNA methyltransferase status should not guide alkylating agent therapy in WD panNETs. © 2017 Wolters Kluwer Health, Inc. All rights reserved. |
